Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data

Sanofi sees faster profit growth on Dupixent, flu vaccine demand

Stock Markets Oct 28, 2022 03:31AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A logo on the Sanofi exhibition space at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France June 15, 2022. REUTERS/Benoit Tessier
 
SNY
+2.42%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
REGN
-1.40%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Ludwig Burger

(Reuters) -French drugmaker Sanofi (NASDAQ:SNY) on Friday forecast faster earnings growth this year on strong demand for its bestselling drug Dupixent and for its flu vaccines, spurring a rise in its battered share price.

Sanofi said it now expects 2022 adjusted earnings per share to grow by about 16%, not taking into account an expected positive currency impact of between 9.5% and 10.5%. It had previously forecast growth of 15%.

It also reported a 26.5% rise in third-quarter business operating income, or adjusted earnings before interest and tax, to 4.5 billion euros ($4.5 billion), well ahead of an average analyst estimate of 4.17 billion.

Sanofi shares had plunged in August after disappointing trial results of a once-promising breast cancer drug candidate, heightening concerns about its development pipeline, while investors also fretted over legal claims that heartburn drug Zantac caused cancer.

The shares have not recovered much and Credit Suisse analysts have said Sanofi is trading about one third below its European peers, relative to estimated 2023 earnings.

Finance chief Jean-Baptiste de Chatillon, who has described the discount as grossly overdone, said on Friday that Sanofi would follow through on its strategy."We know we have some headwinds and we are there to fight them and to demonstrate to our shareholders that we can create more value," he told journalists on a call.

The shares jumped 2% at the open.

CANCER DRUG

But in a further development setback, 1.6 billion euros were written off the value of the most advanced drug project of Synthorx, a U.S. biotech firm Sanofi agreed to acquire for $2.5 billion in 2019. The cancer drug would come to market later than hoped, it said.

As a result, quarterly net income fell 10% to 2.1 billion euros.

Revenue from exzema and asthma drug Dupixent, jointly developed with Regeneron (NASDAQ:REGN), jumped by a currency-adjusted 44.5% to 2.3 billion euros in the quarter, soundly beating an analyst consensus of 2.1 billion.

The company is pursuing further growth for Dupixent in inflammatory skin conditions and smoker's lung, where keenly awaited trial data is expected in the first half of 2023.

Sales from influenza vaccines jumped by a currency-adjusted 32.4% to 2 billion euros, surpassing an analyst consensus of 1.6 billion, on swift uptake of a more expensive new high-dose shot.

CFO de Chatillon said the company also benefited from bringing forward the seasonal production ramp-up and distribution but added that overall appetite in the U.S. population for flu shots was low.

A strong U.S. dollar also boosted the value of overseas group revenue.

($1 = 1.0015 euros)

Sanofi sees faster profit growth on Dupixent, flu vaccine demand
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email